Callan JMB Inc. Stock Price, News & Analysis

Callan JMB (NASDAQ:CJMB) signed a strategic teaming agreement with Attune Biotech on Jan 15, 2026 to provide manufacturing oversight, federal deployment coordination, and commercialization support for Attune's multi-asset therapeutic pipeline. The parties expect approximately $50–$75 million in combined revenue over the next 5 years, with Callan JMB's share projected at about $25–$45 million depending on 50% or 60% profit-sharing by contract scope. Callan JMB cites validated surge-readiness capacity (a 500,000-unit simulation), 24-hour emergency deployment capability and Regional CONUS distribution within 48 hours, aiming to accelerate Attune's federal SNS integration and BARDA/DoD/VA procurement readiness.

Callan JMB (NASDAQ:CJMB) announced a strategic pivot into cold-chain infrastructure to serve GLP-1 pharmaceuticals, initiating phase-one retrofitting of its Texas cGMP facility to add high-capacity pharmaceutical refrigeration and host oral drug delivery equipment.

The company plans proprietary eco-friendly thermal shippers with real-time IoT sensors and 3PL software integration for telehealth home delivery. Management cites a projected $100 billion GLP-1 market by 2030 and highlights a recently extended $9.1 million government contract as financial support for the pivot.

Callan JMB (NASDAQ:CJMB) reported third-quarter results for the period ended September 30, 2025 and provided a business update. Q3 revenue was $1.4M and nine-month revenue was $4.6M. Gross profit was $0.5M for Q3 and $1.8M year-to-date. Operating loss was ($1.9M) in Q3 and ($4.5M) for nine months; cash totaled $2.8M at September 30, 2025.

Business developments include a $1.5M funding increase to extend the City of Chicago emergency-preparedness contract to June 2026 (total contract value $9.1M), formation of an India subsidiary with planned temperature-controlled pharmaceutical warehousing, a preliminary agreement to install oral drug delivery equipment at its Texas cGMP facility, expansion into food sampling, and an upgrade of its Sentry Monitoring System to v4.0 (HTML5).

Callan JMB (NASDAQ:CJMB) entered a preliminary agreement on November 13, 2025 to install an oral drug delivery manufacturer's production equipment at its cGMP facility in Spring Branch, Texas. The collaboration begins a phased effort to combine Callan JMB's cGMP warehousing, licensing, certification, and distribution capabilities with the client's manufacturing technology for fast-dissolving oral strips that offer an alternative to intravenous injections.

The companies are negotiating operational terms while Callan JMB positions this move as part of broader onshoring and manufacturing initiatives with global healthcare partners, including planned efforts with Revival Health.

Callan JMB (NASDAQ: CJMB) announced an expansion of its reclamation and logistics operations into the food sampling sector as part of a multi-variant growth strategy on Nov. 10, 2025. The company will apply its regulated-materials expertise—product integrity, recall readiness, and traceability—to sustainable sampling programs.

Callan JMB cited a partnership with AI platform Keychain (supporting $1B in monthly manufacturing projects and connecting 30,000 manufacturers with 20,000 brands) to accelerate market entry. The release references a global food logistics market > $120B growing 6–10% annually as the expansion rationale.

Callan JMB (NASDAQ:CJMB) announced Sentry 4.0, an upgraded version of its Sentry Monitoring System for temperature-sensitive pharmaceutical storage on Oct 13, 2025.

Sentry 4.0 replaces Java with HTML5, enabling access from any web browser on PC, Mac, iPhone, Android, or tablet without downloads. The system retains 24/7/365 active monitoring, alarm notifications, and compliant reporting while improving user accessibility and consistency across devices. The upgrade is available now to new and existing customers.

Callan JMB (NASDAQ: CJMB) announced that its management team will participate in the LD Micro Main Event XIX on October 19-21, 2025. Presentation is scheduled for October 21, 2025 at 12:00 PM PT at Hotel del Coronado, San Diego, CA. A live webcast will be available at https://ldmicrocasts.com/. For access or questions, contact your LD Micro representative or email CallanJMB@kcsa.com.

Callan JMB (NASDAQ: CJMB), a healthcare logistics services provider, has announced its participation in two upcoming investment conferences in September 2025. The company will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10 at the Lotte New York Palace Hotel, with an on-demand presentation available from September 5.

Additionally, management will participate in the iAccess Alpha Virtual Best Ideas Fall Investment Conference on September 16-17, presenting at 10:30 a.m. ET. The company will conduct one-on-one investor meetings during both conferences.

Callan JMB (NASDAQ: CJMB), a healthcare logistics company, reported Q2 2025 financial results and significant business developments. The company recorded Q2 revenues of $1.7 million and a net loss from operations of $1.4 million.

Key developments include a strategic partnership with Revival Health for integrated supply chain services, launch of an Indian subsidiary with planned temperature-controlled facilities in Pune, and extension of Chicago's emergency preparedness contract through June 2026 with a $1.5 million funding increase to $9.1 million total. The company also appointed Christopher Shields as SVP of Emergency Preparedness & Response and successfully managed a measles outbreak response.

Post-quarter, Callan JMB secured a $25 million equity line of credit to support growth initiatives in GLP-1 pharmaceutical distribution, specialty compounding pharmacy logistics, and premium food packaging solutions.